News & Events

Stay informed about the latest Lumigen news and events.

Lumigen


Life Diagnostics adds three new SPARCL™ assays to their lineup

Life Diagnostics, Inc. adds three new thimidine kinase 1 (TK1) assays to its lineup of over 85 SPARCL assays. The assays were developed for cats (TK1-SP-8), dogs (TK1-SP-4) and humans (TK1-SP-20).

Thymidine kinase 1 (TK1) is an enzyme involved in DNA synthesis. Its expression levels increase in tissues such as tumors that are proliferating. Upon tumor cell death and lysis, TK1 is released into
serum.

  • In cats, TK1 is a potential biomarker for lymphoma.
  • In dogs, it provides a biomarker for lymphoma and mammary tumors.
  • In humans, TK1 provides a biomarker for tumor growth and metastatis.

In addition to fully developed and tested SPARCL assay kits, Life Diagnostics provides HRP and acridan conjugation services for the development of new SPARCL assays. Please visit the Life Diagnostics SPARCL Assay web page for more information.


Life Diagnostics adds a new SPARCL™ assay to their lineup

Life Diagnostics, Inc. adds a new cat C-reactive protein (CRP) assay to its lineup of over 85 SPARCL assays.

In most mammals, CRP (C-reactive protein) is a positive acute phase protein that is elevated in serum following injury, infection and disease. In cats, a three-fold increase in CRP levels is reported after retrovirus infection.

In addition to fully developed and tested SPARCL assay kits, Life Diagnostics provides HRP and acridan conjugation services for the development of new SPARCL assays. Please visit the Life Diagnostics SPARCL Assay web page for more information.